LBSL, Leukoencephalopathies
Conditions
Brief summary
Leukoencephalopathy with brain stem involvement and lactate elevation (LBSL) is a genetic disorder caused by biallelic mutations in the DARS2 gene that encodes mitochondrial aspartyl tRNA synthase.(1, 2) It is characterized by typical abnormalities on MRI of the brain and spinal cord.(3) Clinically, the disorder is heterogeneous and can present in the neonatal period, later in childhood or even in adults.(3) In general it can be stated that the earlier presentations are characterized by rapid progression leading to severe disability and death. Presentation at a later age is typically characterized by a more benign disease course, although considerable disability is common. Clinically, the disease presents as a slowly progressive myelopathy with mainly involvement of the corticospinal tracts and the dorsal columns. Although the natural history has been studied in large cohorts, the rate of progression has not been systematically studied with clinimetric outcome scales or potential surrogate outcomes for spinal cord disease.
Interventions
None listed
Sponsors
M. Engelen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria: * Age \> 16 years * Definite diagnosis of LBSL confirmed by DARS2 mutation analysis. * Able to understand Dutch or English and provide informed consent. * No contra-indications for MRI of brain and spinal cord. Subjects eligible to participate as healthy controls must meet all of the following criteria: * Willing to visit the hospital * 16 years or older * Provision of written informed consent to participate in the study obtained from the participant For the MRI controls: \- No contra-indications for MRI of the brain and spinal cord A potential subject (patient or healthy control) who meets any of the following criteria will be excluded from participation in this study: * Unable to visit the hospital for the follow-up visits * Co-existing neurological disease that can cause pyramidal tract signs making interpretation of acquired data difficult (for instance, multiple sclerosis, stroke, etc)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary outcome is disease progression on all parameters | 5 years | disease progression |
Countries
Netherlands
Contacts
Primary ContactMarije Voermans
Outcome results
None listed